Role of RLIP76 in doxorubicin resistance in lung cancer (review)

Rit Vatsyayan; Pankaj Chaudhary; Poorna Chandra Rao Lelsani; Preeti Singhal; Yogesh C. Awasthi; Sanjay Awasthi; Sharad S. Singhal

doi:10.3892/ijo_00000279

Role of RLIP76 in doxorubicin resistance in lung cancer (review)

Rit Vatsyayan, Pankaj Chaudhary, Poorna Chandra Rao Lelsani, Preeti Singhal, Yogesh C. Awasthi, Sanjay Awasthi, Sharad S. Singhal

Research output: Contribution to journal › Review article › peer-review

45 Scopus citations

Abstract

Lung cancer is still a major cause of cancer deaths in spite of considerable efforts in its systemic therapy. Chemotherapy, along with local irradiation is frequently employed but as a palliative therapy. Inherent and acquired resistance in NSCLC and SCLC towards chemotherapeutic agents further makes chemotherapy an incommodious problem. The resistance mechanisms responsible for inherent DOX-resistance of NSCLC and acquired DOX-resistance in SCLC have been the subject of numerous investigations. This review will focus on the recent studies done for understanding the mechanism(s) of inherent and acquired resistance in NSCLC and SCLC and how these can be exploited for the future development of more effective novel biologic agents for the treatment of lung cancer.

Original language	English
Pages (from-to)	1505-1511
Number of pages	7
Journal	International journal of oncology
Volume	34
Issue number	6
DOIs	https://doi.org/10.3892/ijo_00000279
State	Published - 2009

Keywords

Cancer
Doxorubicin
Drug-resistance
Glutathione conjugate transport
PKCα
RLIP76

Access to Document

10.3892/ijo_00000279

Cite this

@article{d8e85e646fcc405185654d4725a2bdad,

title = "Role of RLIP76 in doxorubicin resistance in lung cancer (review)",

abstract = "Lung cancer is still a major cause of cancer deaths in spite of considerable efforts in its systemic therapy. Chemotherapy, along with local irradiation is frequently employed but as a palliative therapy. Inherent and acquired resistance in NSCLC and SCLC towards chemotherapeutic agents further makes chemotherapy an incommodious problem. The resistance mechanisms responsible for inherent DOX-resistance of NSCLC and acquired DOX-resistance in SCLC have been the subject of numerous investigations. This review will focus on the recent studies done for understanding the mechanism(s) of inherent and acquired resistance in NSCLC and SCLC and how these can be exploited for the future development of more effective novel biologic agents for the treatment of lung cancer.",

keywords = "Cancer, Doxorubicin, Drug-resistance, Glutathione conjugate transport, PKCα, RLIP76",

author = "Rit Vatsyayan and Pankaj Chaudhary and Lelsani, {Poorna Chandra Rao} and Preeti Singhal and Awasthi, {Yogesh C.} and Sanjay Awasthi and Singhal, {Sharad S.}",

year = "2009",

doi = "10.3892/ijo_00000279",

language = "English",

volume = "34",

pages = "1505--1511",

journal = "International Journal of Oncology",

issn = "1019-6439",

publisher = "Spandidos Publications",

number = "6",

}

TY - JOUR

T1 - Role of RLIP76 in doxorubicin resistance in lung cancer (review)

AU - Vatsyayan, Rit

AU - Chaudhary, Pankaj

AU - Lelsani, Poorna Chandra Rao

AU - Singhal, Preeti

AU - Awasthi, Yogesh C.

AU - Awasthi, Sanjay

AU - Singhal, Sharad S.

PY - 2009

Y1 - 2009

N2 - Lung cancer is still a major cause of cancer deaths in spite of considerable efforts in its systemic therapy. Chemotherapy, along with local irradiation is frequently employed but as a palliative therapy. Inherent and acquired resistance in NSCLC and SCLC towards chemotherapeutic agents further makes chemotherapy an incommodious problem. The resistance mechanisms responsible for inherent DOX-resistance of NSCLC and acquired DOX-resistance in SCLC have been the subject of numerous investigations. This review will focus on the recent studies done for understanding the mechanism(s) of inherent and acquired resistance in NSCLC and SCLC and how these can be exploited for the future development of more effective novel biologic agents for the treatment of lung cancer.

AB - Lung cancer is still a major cause of cancer deaths in spite of considerable efforts in its systemic therapy. Chemotherapy, along with local irradiation is frequently employed but as a palliative therapy. Inherent and acquired resistance in NSCLC and SCLC towards chemotherapeutic agents further makes chemotherapy an incommodious problem. The resistance mechanisms responsible for inherent DOX-resistance of NSCLC and acquired DOX-resistance in SCLC have been the subject of numerous investigations. This review will focus on the recent studies done for understanding the mechanism(s) of inherent and acquired resistance in NSCLC and SCLC and how these can be exploited for the future development of more effective novel biologic agents for the treatment of lung cancer.

KW - Cancer

KW - Doxorubicin

KW - Drug-resistance

KW - Glutathione conjugate transport

KW - PKCα

KW - RLIP76

UR - http://www.scopus.com/inward/record.url?scp=67649427320&partnerID=8YFLogxK

U2 - 10.3892/ijo_00000279

DO - 10.3892/ijo_00000279

M3 - Review article

C2 - 19424567

AN - SCOPUS:67649427320

SN - 1019-6439

VL - 34

SP - 1505

EP - 1511

JO - International Journal of Oncology

JF - International Journal of Oncology

IS - 6

ER -

Role of RLIP76 in doxorubicin resistance in lung cancer (review)

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this